Cencora, Inc. COR is well-poised for growth on the back of a robust U.S. Healthcare Solutions business and product launches.

Cencora is attractively valued for potentially strong total returns. Plus, with Walgreens' equity stake in COR reduced to just 6%, COR has more freedom to chart its own course.

Drug distributor Cencora (NYSE:COR) agreed to repurchase shares of its common stock from Walgreens Boots Alliance (NASDAQ:WBA) for ~$50M in concurrence with Walgreens Boots Alliance’s sale of ...

Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has elected Lori J. Ryerkerk as a new independent director, effective June 1, 2025. “Ms ...

Drug distributor Cencora has entered into a definitive agreement to acquire Retina Consultants of America, a management services organization (MSO) of retina specialists, from Webster Equity Partners ...

Cencora intends to repurchase shares from Walgreens Boots Alliance at the price per share equal to the price in the Rule 144 sale.

Walgreens has agreed to pay the government $300 million to settle claims that it unlawfully filled millions of invalid prescriptions.

Downfall Walgreens has been suffering from reduced cash flow and more than half of its $7 billion in net debt is due next year. The company is closing thousands of stores and has embarked on a $1 ...

In a settlement reached with the Justice Department, Walgreens agreed to pay up to $350 million for illegally filling invalid opioid prescriptions.

Walgreens is still a major shareholder of drug and healthcare products distributor Cencora Inc. COR, formerly AmerisourceBergen, which it still owns 10% of, valued at around $4 billion.

Business Warren questions Walgreens sale, warns of potential impact on healthcare access Her concerns follow Sycamore Partners’ proposed $10 billion takeover of the retail pharmacy giant. A ...